VIENNA--(BUSINESS WIRE)--
Poster to be presented on Thursday 18th September 2014 13:00 – 14:00 (Vienna time)
Note: This press release corresponds to EASD abstract #854
Janssen-Cilag International NV (Janssen) today announced results from a post-hoc analysis which showed that at 52 weeks, canagliflozin provided reductions in both HbA1c and body weight in more patients with type 2 diabetes mellitus as an add-on to metformin, when compared with sitagliptin 100mg or glimepiride.1
This analysis used data from two separate randomised, double-blind, active-controlled Phase 3 studies of canagliflozin 100mg and 300mg versus either sitagliptin 100mg or glimepiride. Results showed a greater proportion of patients had reductions in both HbA1c and body weight with canagliflozin 100mg and 300mg compared with sitagliptin 100mg (67.7%, 74.7%, and 50.6%, respectively), or glimepiride (72.4%, 78.5%, and 26.8%, respectively). Canagliflozin 300mg was associated with the greatest reductions in HbA1c and body weight compared to sitagliptin 100mg and glimepiride.
Help employers find you! Check out all the jobs and post your resume.
